Tirzepatide is a once-weekly dual GIP and GLP-1 receptor agonist, sold as Mounjaro and Zepbound. It has more human clinical evidence than any other incretin drug on the market. SURMOUNT covers obesity, SURPASS covers type 2 diabetes, and SURPASS-2 settled the dual-agonist question head-to-head against semaglutide.
Tirzepatide is the first FDA-approved dual agonist of GIP and GLP-1. GIP is a gut hormone that boosts insulin; GLP-1 is a gut hormone that signals fullness. It sells as Mounjaro for type 2 diabetes, approved in 2022, and Zepbound for obesity, approved in 2023.
In the SURMOUNT-1 trial, with 2,539 participants, the top dose produced 22.5% mean body-weight reduction at 72 weeks. In SURMOUNT-4 with continued treatment, that reached 25.3%. In SURPASS-2, tirzepatide beat semaglutide at every dose.
Gastrointestinal side effects hit roughly 60–80% of participants. The cardiovascular outcomes trial, SURMOUNT-MMO, is the remaining open question.
Tirzepatide's approval is one of the cleanest case studies in modern obesity pharmacology. Semaglutide, sold as Wegovy, hit roughly 15% mean body-weight reduction in the STEP-1 trial by activating GLP-1 receptors. Tirzepatide added GIP receptor activity on top of GLP-1 and gained another 7 percentage points.
The dual-agonist idea was simple. GIP might add body-weight reduction beyond what GLP-1 alone can deliver. SURPASS-2 tested that head-to-head and confirmed it. The result made Eli Lilly the dominant company in obesity drugs. It also put dual agonism on the path that retatrutide now extends with a third receptor, glucagon.
This is the comprehensive research guide. We'll cover what tirzepatide is, and why combining GIP and GLP-1 beats either one alone.
Then the SURMOUNT obesity trials at Phase III scale, and what SURPASS showed in type 2 diabetes, abbreviated T2D. Then the head-to-head against semaglutide, the GI tolerability profile, the maintenance data, and where the cardiovascular outcomes question sits.
What is tirzepatide?
Tirzepatide is a 39-amino-acid peptide. Its development code is LY3298176. The brand names are Mounjaro and Zepbound. It carries a C20 fatty-diacid chain that confers an extended half-life, enabling once-weekly subcutaneous dosing in clinical trials.
The molecule activates two receptors at clinical doses. One is the GIP receptor. The other is the GLP-1 receptor. That dual activity is what separates tirzepatide from semaglutide. Semaglutide only hits one of the two.
Researchers have characterized the combination as follows. GLP-1 receptor activity has been shown to reduce gastric emptying rate, stimulate glucose-dependent insulin secretion, and engage central satiety circuits. GIP receptor activity contributes additional postprandial insulin release, modulates adipose lipid handling, and may engage hypothalamic appetite pathways via distinct receptor populations.
The two pathways overlap but aren't identical. Co-activation recruits both. Published data show greater metabolic effects than activating either receptor alone, and SURPASS-2 confirmed that head-to-head.
The success of tirzepatide validates the dual-incretin hypothesis. Engaging GIP and GLP-1 receptors together produces consistently larger body-weight reductions than GLP-1 alone. The tolerability profile stays broadly similar to the established GLP-1 class.
— Melson et al., International Journal of Obesity, 2024, paraphrased
Tirzepatide had the fastest commercial ramp in metabolic medicine. The FDA approved Mounjaro for T2D in 2022. Zepbound followed for obesity in 2023. Global sales surpassed every prior incretin drug within 18 months of launch. The compound effectively defined what successful dual agonism looks like.
Tirzepatide
The same compound cited across the SURMOUNT and SURPASS Phase III trials in this review. Lab-verified identity and purity.
What did the SURMOUNT obesity trials show?
SURMOUNT-1 was the pivotal trial that secured Zepbound's FDA approval. It ran in NEJM in 2022. Jastreboff and colleagues randomized 2,539 adults with obesity into four arms: tirzepatide 5 mg, 10 mg, 15 mg, or placebo.
Adults qualified with a body mass index of 30 or higher, or 27 or higher plus at least one weight-related condition. Body mass index is a weight-to-height ratio. None had T2D. Dosing was once-weekly subcutaneous for 72 weeks.
Here are the headline results.
- 15 mg dose: mean body weight change of −22.5% at 72 weeks
- 10 mg dose: mean body weight change of −21.4% at 72 weeks
- 5 mg dose: mean body weight change of −16.0% at 72 weeks
- Placebo: mean body weight change of −2.4% at 72 weeks
We read the 22.5% figure as the largest documented for any FDA-approvable obesity therapy at the time. It still sets the Phase III benchmark for dual-agonist compounds.
The threshold-response data went even further. On the 15 mg dose, 91% of participants reached 5% body-weight reduction. 57% reached 20%. 36% reached 25%. On placebo, those numbers were 35%, 3%, and 1.5%.
SURMOUNT-4 tackled the follow-up question: what happens when study participants discontinue tirzepatide? Aronne and colleagues ran a 36-week open-label tirzepatide lead-in. Mean body-weight reduction in that phase: 20.9%. They then randomized 670 participants to continued tirzepatide or placebo for 52 more weeks.
Continued tirzepatide added another 5.5% body-weight reduction. Placebo participants regained 14.0%. The total mean weight change from baseline to week 88 was 25.3% on continued treatment versus 9.9% on placebo.
How SURMOUNT-4 shaped the treatment paradigm
The trial established the chronic-treatment paradigm for the GLP-1 class. Published analyses describe incretin pharmacotherapy as long-term maintenance rather than a finite course. SURMOUNT-4's discontinuation data showed weight regain is substantial once you stop. Investigators and prescribers now frame the class like blood-pressure or statin therapy: ongoing, not time-limited.
Other trials in the SURMOUNT program extended these findings to specific groups. SURMOUNT-2 covered T2D with obesity. SURMOUNT-3 layered intensive lifestyle support. SURMOUNT-MMO is the ongoing cardiovascular morbidity and mortality outcomes trial.
How does tirzepatide compare against semaglutide?
SURPASS-2 settled this question, and in our reading it established dual agonism as the dominant paradigm in the class.
Frías and colleagues randomized 1,879 adults with T2D inadequately controlled on metformin. Arms: tirzepatide 5 mg, 10 mg, or 15 mg; or semaglutide 1 mg. All once-weekly for 40 weeks. The primary endpoint was change in HbA1c, a 3-month average of blood sugar, at week 40. Key secondary endpoint: body-weight change.
HbA1c reductions came out as follows: −2.01% on tirzepatide 5 mg, −2.24% on 10 mg, −2.30% on 15 mg, versus −1.86% on semaglutide 1 mg. Every tirzepatide dose outperformed semaglutide. The 15 mg dose delivered nearly half a percentage point more HbA1c reduction.
Body-weight reduction showed an even larger gap. Tirzepatide 15 mg produced 11.2 kg mean body-weight reduction. Semaglutide 1 mg produced 5.7 kg. That's nearly double. We'd say SURPASS-2 ended any serious debate about whether dual agonism produces larger metabolic effects than single GLP-1 agonism.
Where this falls short
SURPASS-2 used semaglutide at 1 mg, the highest T2D dose. It didn't use 2.4 mg, the obesity dose in Wegovy and STEP-1. No direct head-to-head between tirzepatide 15 mg and semaglutide 2.4 mg for obesity has been published.
The cross-trial comparison lines up with SURPASS-2: SURMOUNT-1 at 22.5% against STEP-1 at 14.9%. But cross-trial isn't head-to-head. The strongest claim we can make is that at matched clinical doses, dual agonism reliably beats single GLP-1.
What about GI tolerability?
Tirzepatide's side-effect profile sets the standard for the dual-agonist class. In SURMOUNT-1, common GI events on the 15 mg dose included nausea in roughly 33% of participants, diarrhea in 22%, constipation in 17%, and vomiting in 12%. Most events were mild-to-moderate, transient, and clustered during the dose-titration phase.
Placebo-arm rates were lower but not negligible: nausea 10%, diarrhea 9%, constipation 6%. That's roughly the background rate of GI symptoms you'd see in any large adult population.
Treatment discontinuation rates ran 4–7% across the active arms in SURMOUNT-1. The placebo rate was 3%. That's a small but real tolerability cost, and lower than you might expect. The vast majority of participants who started tirzepatide finished the 72-week trial.
Tirzepatide's gastrointestinal adverse event profile is consistent with the established GLP-1 class. Mostly mild-to-moderate nausea, diarrhea and constipation during dose escalation, largely resolving with continued treatment. Dose-titration protocols are the clinical answer to most early-phase tolerability problems.
— Jastreboff et al., NEJM, 2022, paraphrased
Published clinical protocols and the approved prescribing information describe a graduated dose-escalation approach. Trial arms typically used four-week titration intervals. Discontinuation analyses point to the first 12 to 16 weeks as the highest-risk window for adverse-event withdrawal. That fits the transient GI events seen during up-titration.
What about cardiovascular outcomes?
Cardiovascular outcomes are the open question for tirzepatide, and we don't have the answer yet. SURMOUNT-MMO is the dedicated cardiovascular morbidity and mortality outcomes trial. It enrolls roughly 15,000 participants with obesity and established cardiovascular disease. It's the closest analog to semaglutide's SELECT trial. The primary readout is expected over the next several years.
Strong implication from SURMOUNT-1 and SURMOUNT-4: tirzepatide should produce cardiovascular risk-factor improvements roughly matched to the body-weight reduction it produces. Blood pressure, lipid panels, waist circumference, and liver-fat markers all improve. But until SURMOUNT-MMO reads out, we'd put the cardiovascular claim at "highly plausible" rather than "demonstrated." That's the same framing semaglutide carried before SELECT.
SURPASS-CVOT is the parallel trial on the diabetes side. The T2D cardiovascular question is a bit different. T2D pharmacotherapy carries a regulatory expectation of cardiovascular safety demonstrated in dedicated outcomes trials. That expectation comes from the FDA's 2008 guidance after the rosiglitazone controversy.
Tirzepatide
39-aa dual GIP/GLP-1 agonist with C20 fatty-diacid acyl chain. The same reference compound used across the cited SURMOUNT and SURPASS trials. COA available with each lot.
Regulatory status and clinical positioning
Tirzepatide holds two FDA approvals: Mounjaro for T2D in 2022, and Zepbound for obesity in 2023. The approved obesity indication follows SURMOUNT-1, covering a BMI of 30 or higher, or 27 or higher with at least one weight-related condition.
Unlike retatrutide, which stays investigational, you can get tirzepatide by prescription in the US, EU, Canada and most other major markets. The global supply constraints of 2023–2024 have substantially eased.
SURMOUNT-4 established that stopping tirzepatide produces substantial weight regain. Investigators now frame it as long-term maintenance rather than a finite course, on the model of blood-pressure or lipid-lowering drugs. Week 16 response, meaning a body-weight reduction of 5% or more, shows up in analyses as an early predictor of long-term success.
The SURMOUNT and SURPASS programs also documented secondary endpoints across research cohorts: lower systolic blood pressure, better lipid parameters and smaller waist circumference. We read those as consistent with the metabolic improvement you'd expect from that much weight change.
What to know now
- Mechanism: Dual agonist at GIP and GLP-1 receptors. The first approved drug to engage both incretin pathways.
- SURMOUNT-1 headline: 22.5% mean body-weight reduction at 72 weeks on the 15 mg dose. 91% of participants reached 5% body-weight reduction.
- SURMOUNT-4 maintenance: 25.3% overall mean body-weight reduction at week 88 with continued treatment. 14% regain on placebo discontinuation.
- SURPASS-2 head-to-head: Tirzepatide beat semaglutide 1 mg at every dose on HbA1c and body-weight reduction in T2D.
- Tolerability: ~33% nausea, ~22% diarrhea, ~12% vomiting at 15 mg dose. Mostly mild-to-moderate. 4 to 7% discontinue for adverse events.
- Regulatory status: FDA-approved for T2D (Mounjaro, 2022) and obesity (Zepbound, 2023). Globally available.
- Cardiovascular outcomes: SURMOUNT-MMO ongoing. A SELECT-equivalent CV benefit demonstration is still pending.
What we’re watching
Four things over the next 18 to 24 months. First, the SURMOUNT-MMO cardiovascular outcomes readout. The question is whether tirzepatide matches semaglutide's SELECT reduction in major adverse cardiovascular events. Second, the retatrutide Phase III TRIUMPH readouts and the eventual head-to-head data.
Tirzepatide's positioning shifts depending on whether it's the current best-in-class or the previous one. Third, oral incretin formulations. Orforglipron and similar oral candidates are working through Phase III and could move tirzepatide's place in the prescribing algorithm.
Fourth, the durability question past two years. Tirzepatide's longest published data runs 88 weeks. Multi-year sustainability is the next frontier.
References
- Jastreboff, A. M., Aronne, L. J., Ahmad, N. N., et al. (2022). Tirzepatide once weekly for the treatment of obesity. New England Journal of Medicine, 387(3), 205–216. https://doi.org/10.1056/NEJMoa2206038
- Frías, J. P., Davies, M. J., Rosenstock, J., et al. (2021). Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes. New England Journal of Medicine, 385(6), 503–515. https://doi.org/10.1056/NEJMoa2107519
- Aronne, L. J., Sattar, N., Horn, D. B., et al. (2024). Continued treatment with tirzepatide for maintenance of weight reduction in adults with obesity: The SURMOUNT-4 randomized clinical trial. JAMA, 331(1), 38–48. https://doi.org/10.1001/jama.2023.24945
- Jastreboff, A. M., Kaplan, L. M., Frías, J. P., et al. (2023). Triple-hormone-receptor agonist retatrutide for obesity — A Phase 2 trial. New England Journal of Medicine, 389(6), 514–526. https://doi.org/10.1056/NEJMoa2301972
- Melson, E., Ashraf, U., Papamargaritis, D., & Davies, M. J. (2024). What is the pipeline for future medications for obesity? International Journal of Obesity, 49(3), 433–451. https://doi.org/10.1038/s41366-024-01473-y